Electra Therapeutics, Inc (ETRA) Stock
NYSE · ETRA
11.43
Fundamentals
Market cap
$724.96M
Price / Earnings ratio
-11.7x
Price / Sales ratio
N/A
Price / Book ratio
-3.3x
Return on assets
N/A
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Stocktwits
Biotech Week Ahead: XLV Beats The Market — Here Are The Stocks, Readouts And Events To Watch Next
NeutralETRASeptember 21, 2026
StocktwitsNeutral
Biotech Week Ahead: XLV Beats The Market — Here Are The Stocks, Readouts And Events To Watch Next
ETRA

Reuters
Electra Therapeutics targets $977.6 million valuation in US IPO
NeutralETRASeptember 14, 2026
ReutersNeutral
Electra Therapeutics targets $977.6 million valuation in US IPO
ETRA
Technicals
Not enough data
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy0
Strong Buy0
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
% positive news of 2 articles
published over the past 14 days
Latest news

Stocktwits
Biotech Week Ahead: XLV Beats The Market — Here Are The Stocks, Readouts And Events To Watch Next
NeutralETRASeptember 21, 2026
StocktwitsNeutral
Biotech Week Ahead: XLV Beats The Market — Here Are The Stocks, Readouts And Events To Watch Next
ETRA

Reuters
Electra Therapeutics targets $977.6 million valuation in US IPO
NeutralETRASeptember 14, 2026
ReutersNeutral
Electra Therapeutics targets $977.6 million valuation in US IPO
ETRA
About Electra Therapeutics, Inc
The company is a late clinical-stage biopharmaceutical firm focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer.
CEODr. Quehuong Dong M.B.A., Pharm.D.
HeadquartersSouth San Francisco, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Quehuong Dong M.B.A., Pharm.D. | President, CEO & Director | 1982 |
| Mr. Gary S. Koe Ph.D. | Chief Technology Officer | 1964 |
| Dr. Kim-Hien Dao D.O., Ph.D. | Chief Medical Officer | 1973 |
| Mr. Christopher W. Clark C.F.A. | Chief Financial Officer | 1978 |
| Dr. Graham Parry Ph.D. | Chief Scientific Officer | 1964 |
Fundamentals
Valuation
Market cap$724.96M
Price-to-sales ratioN/A
Price-to-book value-3.29
Price-earnings ratio-11.70
Return on EquityN/A
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-1,408.52
Income Statement
Average volume1,539,550
EBITDAN/A
1 year high (52w)$15.50
1 year low (52w)$11.71
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
Not enough data
What the experts say
0 Wall Street Analyst Ratings
N/A
0% Buy
0% Hold
0% Sell
Target price
$0.00
Est return
0.00%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -12.8 |



